← Back to Feb 2014

links imageIN THE SPOTLIGHT:

ISHLT 2014 in Sunsational San Diego!

Featuring Meeting Highlights in Pulmonary Transplantation and Infectious Diseases

At ISHLT 2014, there will be a number of symposia with primary content of interest for any lung transplant or infectious diseases healthcare professional, as well as many addressing basic science, nursing, pharmacy, pediatrics and pulmonary hypertension, which will have content of interest to the lung transplant and infectious diseases specialists. Find out which sessions will be of most interest to you, and plan your trip to San Diego TODAY!

Thursday, April 10, 2014:

PRE-MEETING SYMPOSIUM 4: Lung Transplant Candidate Selection: Have We Pushed the Envelope Too Far?
Existing selection criteria aim to discriminate those expected to thrive from those anticipated to do poorly following lung transplantation. The last 5 years has witnessed an explosion in lung transplantation for older and sicker candidates who fall outside of selection guidelines. Since these criteria were developed through consensus expert opinion and established, epidemiological studies have confirmed increased mortality for certain criteria including age above 55, extremes of weight, and, possibly, frailty. The common thread underpinning these observations is body composition derived inflammation. This symposium aims to reevaluate key selection criteria through the lens of body composition and inflammation. It will also explore intervention strategies that may be applicable to all lung transplant candidates.

PRE-MEETING SYMPOSIUM 5: Lung Transplantation: Decoding Early Engraftment Events That Control Survival
It is becoming clear that many significant risk factors for lung transplant rejection occur within the early engraftment period. Also, it is apparent that the current immunosuppression strategies have not significantly improved patient survival in the last decade. Recent developments in experimental lung transplantation have helped uncover novel mechanisms that link innate and acquired immunity following engraftment. In this session, we propose to present new insights into ischemia reperfusion injury, T cell activation, and humoral immunity that impact the maintenance of allograft tolerance as well as long-term survival, using a clinical case to guide the presentations. The goal of these presentations is to educate the wider transplant community of potential new therapeutic targets and translational opportunities for the development of novel immunosuppression approaches for lung transplant recipients.

PRE-MEETING SYMPOSIUM 9: Invasive Fungal Infections Among Cardiothoracic Transplant Recipients: Consensus Guidelines and Recommendations from the ISHLT Fungal Expert Panel
Learn more about the fungus among us in this session. A consensus and guidelines for invasive fungal infection developed by the ISHLT fungal expert panel will present a review of the literature and recommendations regarding the epidemiology, diagnostics, therapeutics and prophylaxis of fungal infections among cardiothoracic transplant recipients.

PRE-MEETING SYMPOSIUM 10: The Many Faces of Chronic Lung Allograft Dysfunction
Lung allograft dysfunction occurs in many different ways. These present and progress in differing fashions; treatment, although not well developed, could be different between different types. This session will address these issues.

PRE-MEETING SYMPOSIUM 15: Bad Bugs? Optimize the Drugs! combines brief illustrative case presentations followed by state-of-the-art lectures reviewing issues and controversies in antiviral, antibacterial, antifungal and antimycobacterial therapeutic drug monitoring (TDM). Although there is a small amount of published information on TDM and azole antifungal agents in heart lung transplantation, the antibacterial and antiviral drugs have been very neglected. Inappropriate dosing may lead to treatment failure, toxicity and the development of resistant organisms, both of which can be catastrophic in the transplant setting.

PRE-MEETING SYMPOSIUM 16: Ex-Vivo Lung Perfusion (EVLP): Evolving Strategy For Improved Donor Lung Management
The last 5 years have witnessed an exponential rise in the use of ex-vivo lung perfusion (EVLP) for both basic scientific research and clinical practice. Various ex-vivo devices are now available for supporting donor lungs. This symposium aims to provide a timely update on the following aspects of EVLP: Expanding the donor organ pool; Cold storage with subsequent functional assessment versus primary physiological support; Limiting cold ischaemia; Sanguinous versus asanguinous perfusion; Repair and reconditioning of poor donor organs; Improving functional assessment of donor organs; Supporting lungs from DCD; and Clinical trials. The symposium also aims to meet the significant educational need of fully appreciating the principles and practice of EVLP. An additional benefit from this educational session is to stimulate wider evidence-based clinical adoption of this technology to expand the donor pool, improve donor organ function, and potentially extend graft and recipient survival.

PRE-MEETING SYMPOSIUM 22: Global Perspectives on Donation after Circulatory Determination of Death in Lung Transplantation
It remains true that most donor lungs offered for transplant are discarded with substantial patient numbers dying on the waiting list. DCD has become widely accepted now in lung transplantation with increased experience. EVLP as a new method of treating and evaluating marginal lungs is being used effectively as well and will be more widely adopted. However, the increased complexity and cost of EVLP is one reality that may limit clinical adoption. What is the best way forward to join these practices and employ EVLP most effectively to quickly impact lungs transplanted? Are these technologies additive, competing, should they be combined international perspective? This symposium will explore these issues.

PRE-MEETING SYMPOSIUM 23: State of the Art Update on Infectious Disease Issues in Pediatric Thoracic Transplantation
The infectious disease sessions at ISHLT traditionally have focused on adults rather than children. Some of the pediatric responses to infections are quite disparate from those of adults. This session will provide a state of the art update based on the latest data in pediatrics.

Friday, April 11, 2014:

SUNRISE SYMPOSIUM 4: Controversies in Lung Transplantation
For the coffee-fueled early birds, this symposium will address some controversial areas in lung transplantation in the form of Pro and Con debates. This is a very popular format and stimulates great discussions.

SUNRISE SYMPOSIUM 5: What You Always Wanted to Know About LISH (Laboratory Tests, Infectious Agents, Special Situations, Hidden Infections) but Were Afraid to Ask
In the field of infectious diseases there are many accepted standards for treatment and diagnoses. However we do not always know the real explanation for them nor do we question them. This symposium will attempt to clarify several main topics in ID from laboratory to therapy.

CONCURRENT SYMPOSIUM 26: Infections in Mechanical Circulatory Support Devices - Understanding and Conquering the Beast
This symposium will focus on pathogenesis, recent guidelines on diagnosis, as well as medical and surgical approaches for the management and prevention of Mechanical Circulatory Support Device-associated infections.

Saturday, April 12, 2014:

SUNRISE SYMPOSIUM 9: CMV Infection in Lung Transplant Recipients: Are We Ready for Personalized Medicine?
CMV infection continues to be a clinical challenge in select lung transplant recipients (LTRs) despite advancements in prevention and treatment strategies. Identifying LTRs at risk for recurrent viral replication and/or allograft injury is essential for adjusting antiviral therapies and improving long-term outcomes. In this session, the latest in translational bench-to-bedside approaches used to evaluate those at risk for active CMV infection and its sequelae will be discussed. By the completion of this session, attendees will be familiar with measurements of CMV-specific immunity to monitor and predict CMV outcomes in higher-risk LTRs, promising new therapies to treat emerging CMV resistance, and pro/con viewpoints for correlating CMV replication in the lung allograft and the risk of BOS.



Sunday, April 13, 2014:

SUNRISE SYMPOSIUM 15: High-Risk Donor: Extending our Criteria in Times of Organ Shortage
Transmission of viral infections through solid organ transplantation can lead to adverse outcomes for recipients. Despite the use of highly sensitive serologic tests for most common infections, the use of organs from high-risk donors remains controversial. Understanding the risk of transplanting the organ of a high-risk donor on the post-transplant outcome is important to judiciously advice candidates on the waiting list and to provide appropriate post-transplant care.

Share via:

links image    links image    links image    links image